Making Medicine

Incubate Coalition

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

  1. 2d ago

    FDA Leadership, China & The Future of American Biotech

    🇺🇸 FDA leadership, China's growing role in clinical trials, NIH research, and biotechnology innovation are shaping the future of American medicine. This week on the Making Medicine Podcast, John Stanford breaks down the latest developments in the search for the next FDA Commissioner, including the three reported finalists: Dr. Heidi Overton, White House health policy adviser; Dr. Jeffrey Vacirca, oncologist and CEO of New York Cancer & Blood Specialists; and Dr. Stephen Ferrara, Deputy Assistant Secretary of Defense for Health Affairs and former CIA Chief Medical Officer. John explores what the next FDA leader could mean for regulatory modernization, drug development, and the future of American biotechnology. This episode covers: 🔹 The latest FDA Commissioner search and what the three finalists could mean for the agency 🔹 Congressional hearings on FDA modernization and biomedical innovation 🔹 China's rapid expansion in global clinical trials and growing biotech competitiveness 🔹 Patent eligibility reform, intellectual property protections, and the future of biotech investment 🔹 NIH research funding, research security, and protecting American scientific leadership 🔹 FDA Approvals Corner featuring new therapies from Rigel Pharmaceuticals, BeOne Medicines, AstraZeneca, Gilead Sciences, AbbVie, Haisco Pharmaceutical Group, Shionogi, Wockhardt, Bayer, GSK, and Viridian Therapeutics From FDA leadership and congressional hearings to intellectual property, research security, and global competition with China, this episode examines the policy decisions shaping the future of biomedical innovation. John also highlights why protecting NIH-funded research, modernizing the FDA, and strengthening America's innovation ecosystem remain essential to delivering the next generation of medicines and improving patient access. The episode concludes with another edition of FDA Approvals Corner, celebrating newly approved therapies across oncology, infectious disease, cardiovascular medicine, rare diseases, anesthesia, and diagnostic imaging, highlighting the continued progress being made for patients around the world. Watch the full episode and Join the Conversation ⬇️ Who should lead the FDA? How should America compete with China's growing biotech industry? What role should NIH-funded research play in future drug development? Drop your thoughts in the comments below 👇 👍 Like and subscribe for more conversations on biotechnology, healthcare policy, FDA news, clinical trials, pharmaceutical innovation, and life sciences. If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps: 00:00 Why American Biotech Matters 01:35 FDA Leadership Search 03:14 FDA & China Hearings 05:13 Clinical Trial Competition 06:25 Patent Reform Explained 07:52 NIH Research Security 08:58 Why NIH Funding Matters 09:19 FDA Approvals Corner 11:32 July FDA Outlook DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #fda #biotech #healthcarepolicy #clinicaltrials #NIH

  2. Jul 9

    Japan's Biotech Transformation: Drug Pricing, Clinical Trials & Global Investment

    Japan's biotech industry is at a crossroads. Drug pricing reform, clinical trials, venture capital investment, and life sciences policy are all in flux as the country tries to figure out its path forward.  This week on the Making Medicine Podcast, guest host John Guy, Incubate's Policy Director, is joined by John Gutierrez of Ascenta Capital and Josh Lipscomb, Incubate’s International Programs Manager, to recap their recent biotechnology delegation to Japan. After meeting with government officials, investors, startup founders, and policymakers across Tokyo, they discuss the challenges Japan faces in strengthening its biotech ecosystem and the open question of whether pharmaceuticals can become a bigger driver of economic growth. This episode covers  🔹 Japan's biotech growth strategy — and its limitations  🔹 Drug pricing reform and the slow pace of pharmaceutical innovation 🔹 Drug lag and ongoing barriers to patient access 🔹 International clinical trials and the difficulty of attracting startup investment 🔹 Venture capital gaps in Japan's life sciences ecosystem 🔹 Takeaways from the BIO International Convention One of the takeaways is that Japan has moved past simply acknowledging its biotech challenges and has started attempting policy reforms. The discussion explores whether changes to drug pricing, international clinical trial access, startup support, and venture capital could meaningfully accelerate innovation, or whether structural hurdles will continue to slow patient access to new medicines. The conversation also touches on Japan's presence at the BIO International Convention, where government leaders, investors, and entrepreneurs made the case for the country as a destination for biotech investment — even as it continues to compete with more established markets. As global competition for innovation intensifies, it remains to be seen how much ground Japan can gain in the future of drug development. Watch the full episode and Join the Conversation ⬇️ Can Japan become one of the world's leading biotech ecosystems? Is drug pricing reform the key to attracting more biotech investment? What lessons can other countries learn from Japan's approach to life sciences innovation? Drop your thoughts in the comments below 👇   👍 Like and subscribe for more conversations on biotechnology, healthcare policy, drug pricing, venture capital, clinical trials, pharmaceutical innovation, and global life sciences. If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Tmestamps 00:00 Japan Drug Lag Explained  01:45 Japan's Biotech Growth Strategy 06:10 Drug Pricing Reform 08:24 Why Japan Misses New Medicines 11:42 Japan's Innovation Advantage 13:35 Building Japan's Startup Ecosystem 14:42 BIO International Convention 16:28 Japan's Global Investment Strategy 19:00 What's Next for Japan Biotech 22:44 Outro DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #biotech #Japan #DrugDevelopment #ClinicalTrials #HealthcarePolicy #Making Medicine

  3. Jul 2

    Maria Thacker Goethe on Biotech Growth, Clinical Trials & US Competitiveness

    Georgia's life sciences industry is growing fast. Biotech manufacturing, clinical trials, workforce development, and healthcare policy are reshaping America's innovation economy. This week on the Making Medicine Podcast, John Stanford sits down with Maria Thacker Goethe, President and CEO of Georgia Life Sciences, to discuss why Georgia has become one of the fastest-growing biotechnology hubs in the United States and what it will take to keep America globally competitive. Fresh off the BIO International Convention, Maria shares how policy conversations have evolved from niche discussions to a central focus for biotech leaders. From clinical trial modernization and manufacturing investments to workforce shortages, drug pricing, and China's expanding biotechnology capabilities, she explains why policy decisions now directly influence innovation, investment, and patient access. This episode covers: 🔹 Georgia's rise as a national life sciences and biomanufacturing hub 🔹 Why workforce development has become biotech's biggest challenge 🔹How universities, industry, and government are building the next generation of talent 🔹China's growing influence in biotechnology and global drug development 🔹Drug pricing, innovation, and protecting investment in breakthrough medicines 🔹 Operation Trial Blazer and the future of faster clinical trials 🔹Why collaboration remains America's greatest competitive advantage One of the biggest takeaways is that biotechnology is no longer just about scientific discovery. It's about building an ecosystem where policy, workforce, capital, manufacturing, and research all work together. Maria explains why states like Georgia are proving that biotech leadership isn't limited to Boston or San Diego, and why strategic investments in people and infrastructure will determine America's future competitiveness. Whether discussing clinical trial reform, rare disease innovation, or the balance between national security and global scientific collaboration, this conversation highlights how today's policy decisions will shape tomorrow's medical breakthroughs. Watch the full episode and Join the Conversation ⬇️ Can Georgia become one of America's top biotech hubs? What is the biggest challenge facing US biotech today: workforce, capital, or policy? Should America focus more on innovation than restrictions to stay globally competitive? Drop your thoughts in the comments below 👇  👍 Like and subscribe for more conversations on biotechnology, healthcare policy, FDA modernization, clinical trials, workforce development, drug pricing, life sciences investment, and healthcare innovation. If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps 00:00 Operation Trial Blazer & US Clinical Trials 05:01 BIO 2026 and US Biotech Competitiveness 08:46 Georgia's Life Sciences Growth  12:07 Building the Next Biotech Hub 18:15 Drug Pricing and Biotech Innovation  21:29 Operation Trial Blazer Reforms 22:11 China and US Biotech Competition  26:18 Biotech Workforce Development 30:06 Why Biotech Needs Skilled Trades 33:21 Georgia Life Sciences Summit 35:42 Closing Thoughts DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #biotech #lifesciences #healthcarepolicy #clinicaltrials #drugdevelopment

  4. Jun 25

    Why FDA Instability is Driving Biotech Capital Abroad — What Investors Are Saying

    FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad. In case you missed it: We are bringing one of our most critical recent conversations to unpack how regulatory uncertainty is shifting the future of medicine. FDA instability is reshaping biotech investment decisions in real time. Across the board, investors are recalibrating risk, pulling back on funding, and even shifting capital abroad. In this episode of the Making Medicine Podcast, John Stanford is joined by Rachel Sher of Manatt Health to unpack new, original research conducted with investors across the biotech ecosystem. The goal was simple: move beyond speculation and understand whether recent leadership changes, staffing cuts, and policy uncertainty at the FDA are actually dictating investor behavior. The signal is clear. Across venture capital, public equity, private equity, and industry investors, the vast majority agree that recent changes at the FDA have fundamentally altered how they allocate capital and view the attractiveness of U.S.-based drug development. This Episode Covers Four Major Themes: 🔹 Regulatory Instability: Growing investor concern over shifting FDA standards. 🔹 Shifting Portfolios: A reduced appetite for funding complex product categories like gene therapy and vaccines. 🔹 Global Competition: Increasing attention and capital flowing toward China and other international markets. 🔹 The Innovation Pipeline: Broader fears that instability across agencies like the NIH and FDA will weaken long-term medical breakthroughs. At the center of it all is one core issue: regulatory predictability. When investors lose confidence in policy clarity and institutional knowledge, the consequences extend far beyond individual companies—they dictate where innovation happens next. Even with these concerns, investors still want to back innovation in the United States. The question is whether policymakers and regulators can restore the stability and trust that made the U.S. the global leader in biotech in the first place. Watch for a grounded conversation on what investors are really saying, what it means for the biotech ecosystem, and why FDA predictability matters more than ever.  Check out the full report https://www.incubatecoalition.org/post/one-pager-complete-report-regulatory-instability-at-fda-is-reshaping-biotech-investment Join the Conversation ⬇️ Do you think FDA instability is already changing the future of biotech investment? Are investors right to look abroad when U.S. regulatory signals become less predictable? What matters more right now: speed, stability, or scientific consistency? Drop your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more biotech and healthcare policy coverage. Time Stamps 00:00 Intro & Disclaimer 00:16 Investors Say FDA Changes Are Impacting Decisions 03:22 How We Surveyed Investors (Research Design) 07:27 Theme 1: FDA Instability & Investor Uncertainty 10:22 Investors Repricing Risk in Biotech 12:05 “Chaos Is the Only Thing” – Investor Quote 13:00 Theme 2: Pullback from Gene Therapy, Vaccines, Oncology 14:28 Theme 3: Capital Shifting Abroad (China & Competition) 17:02 Theme 4: NIH Cuts & Long-Term Innovation Risk 25:24 Key Takeaway: Regulatory Predictability Drives Investment DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #Biotech #FDA #BiotechInvesting #HealthcarePolicy #DrugDevelopment #makingmedicine

  5. Jun 18

    China’s Biotech Rise: What Tim Scott Saw Inside Shanghai

    China's biotech innovation is accelerating. Clinical trials, NIH funding, and global competition are reshaping healthcare. Biocom’s President & CEO Tim Scott explains why America should focus on "playing to win" rather than "playing not to lose." China’s biotech industry is moving faster than many policymakers realize. From investigator-initiated clinical trials and massive patient registries to government-backed investment strategies, China is rapidly becoming a major force in global drug development. This week on the Making Medicine Podcast, John Stanford sits down with Tim, fresh off a biotech delegation trip to Shanghai. He shares firsthand observations from China's rapidly growing life sciences ecosystem, what surprised him most, and what American biotech leaders should learn from the experience. This Episode Covers 🔹 Why major pharmaceutical companies are increasingly sourcing innovation from China 🔹 How China’s investigator-initiated trial system accelerates drug development 🔹 The role of patient registries and trial-ready cohorts 🔹 Why China is becoming a global biotech powerhouse 🔹 The debate over biosecurity, protectionism, and global scientific collaboration 🔹 NIH funding, workforce development, and America’s innovation advantage 🔹 How the United States can remain the world leader in biotechnology One of the most thought-provoking moments comes when Tim compares the biotech race to the New York Knicks' championship run, arguing that America must focus on "playing to win" through investment, innovation, NIH funding, and scientific leadership rather than simply "playing not to lose" by slowing competitors down. The analogy becomes a powerful framework for understanding the choices facing US policymakers as China continues to expand its role in global drug development. The conversation ultimately challenges listeners to think beyond today's headlines and consider how the United States can maintain its leadership in biotechnology while continuing to deliver breakthrough medicines for patients around the world. The question is no longer whether China matters in biotech. The question is how America responds. Will the US continue playing to win through investment and innovation, or will it focus primarily on slowing competitors down? Watch the full episode and Join the Conversation ⬇️ Do you believe China is now a permanent biotech superpower? Can the United States maintain its leadership in biomedical innovation? Should scientific collaboration continue despite growing geopolitical tensions? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more biotech and healthcare policy coverage. Timestamps 00:00 China Biotech Competition 01:00 California Life Sciences Leadership 07:45 Pharma Licensing Deals in China 13:10 China Clinical Trials Explained 20:00 Drug Pricing and Biotech Innovation 23:18 Shanghai Biotech Ecosystem 25:28 China's Biotechnology Growth Strategy 35:28 Biosecurity and US-China Biotech Policy 40:20 Playing to Win in Biotech 42:10 Knicks Analogy and Innovation Leadership 43:20 NIH Funding and American Innovation 47:35 AI, China and the Future of Biotechnology 49:58 Outro  DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #Biotech #China #DrugDevelopment #ClinicalTrials #HealthcarePolicy

  6. Jun 11

    Patient Advocacy, FDA Partnerships & Building the Infrastructure of Drug Discovery

    Rare diseases. Patient advocacy. Drug development. FDA partnerships. Clinical trials. Patient organizations have evolved into powerful engines of drug development, building registries, funding research, shaping clinical trial design, and partnering with regulators to accelerate new treatments. This week on the Making Medicine Podcast, John Stanford sits down with Lisa Bonebrake, Executive Director of the Alport Syndrome Foundation, and Janis Naeve, world-class VC and Co-Founder & Partner of Bright Frontier, to discuss the evolving, high-impact role of patient organizations in modern drug development. Patient advocacy groups are building the critical data and clinical infrastructure required to advance medical research. Lisa shares how the Alport Syndrome Foundation is directly de-risking clinical trials, building global patient registries, and driving the ASCENT Initiative, a historic public-private partnership with the FDA to establish surrogate endpoints for kidney disease. The discussion also explores the venture capital perspective with Janis Naeve, highlighting why investors view patient-led data infrastructure as a "highway" for innovation, how pharmaceutical companies can successfully integrate patient feedback into trial design, and why establishing clear regulatory pathways is vital to accelerating rare disease treatments. This Episode Covers 🔹 Why patient advocacy groups are the new infrastructure of drug discovery 🔹 The real impact of Alport syndrome and the importance of early genetic testing 🔹 The ASCENT Initiative and establishing surrogate endpoints with the FDA 🔹 The impact of Alport syndrome and the importance of early genetic testing 🔹 Why pharmaceutical companies must include patient voices in clinical trial design  🔹 The venture capital perspective on funding rare disease innovation 🔹 Regulatory clarity and de-risking biotech investment 🔹 How public-private partnerships accelerate the timeline for lifesaving treatments Patient advocates are no longer passive charities, they are the essential infrastructure of modern drug discovery. This conversation serves as a blueprint for the future of healthcare policy, exploring how rare disease organizations are partnering with the FDA, saving pharma millions by rescuing flawed clinical trials, and driving venture capital investment to accelerate lifesaving treatments. Join the Conversation ⬇️ Should patient organizations have a larger role in shaping FDA regulatory pathways? What's the biggest obstacle preventing more rare disease drug development? How can policymakers better support patient-led research infrastructure? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more biotech and healthcare policy coverage. Timestamps 0:00 - The Real ROI of Patient Advocacy 0:26 - Welcome to the Making Medicine Podcast 1:52 - Breaking News in Alport Syndrome Research 4:03 - What is Alport Syndrome? 5:58 - Redefining the Role of Patient Organizations 9:09 - A VC Investor’s Perspective on Rare Disease 11:38 - The ASCENT Initiative & FDA Public-Private Partnership 18:03 - Understanding Surrogate Endpoints in Clinical Trials 25:19 - How to Build a Fearless Patient Advocacy Group 30:26 - Why Pharma Needs to Listen Directly to Patients 35:31 - Educating the Biotech Industry on Patient Integration 39:35 - Key Takeaways for Policymakers and Investors DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #rarediseases #drugdevelopment #clinicaltrials #fda #biotech #patientadvocacy #makingmedicine #podcast

  7. Jun 4

    Healthcare Costs, PBMs & Why Manufacturers Oppose Drug Price Controls

    Healthcare costs. PBM reform. Drug price controls. FDA stability. American manufacturing. This week on the Making Medicine Podcast, John Stanford sits down with Charles Crain, Vice President of Domestic Policy at the National Association of Manufacturers, to discuss a new report examining the rising cost of healthcare and its impact on American manufacturers. Manufacturers provide health coverage to millions of workers, making healthcare affordability a major business concern. But according to NAM, the solution isn't limiting pharmaceutical innovation. Instead, the conversation focuses on PBM reform, 340B program transparency, regulatory certainty, preventative care, and policies that lower costs without undermining America's leadership in medical innovation. The discussion also explores why FDA stability matters beyond the biotech sector, how regulatory uncertainty affects long-term investment, and what policymakers should prioritize to strengthen American competitiveness in the face of growing global competition.  This Episode Covers: 🔹 Why healthcare costs are manufacturers' top business concern 🔹Why NAM opposes pharmaceutical price controls 🔹The real drivers of rising healthcare costs 🔹PBM reform and prescription drug transparency 🔹The 340B program and hospital incentives 🔹Why FDA stability matters for innovation 🔹Regulatory certainty and biotech investment 🔹Manufacturing, R&D, and American competitiveness 🔹Lessons from COVID supply chain vulnerabilities 🔹How to compete with China through innovation At the center of this conversation is a simple question: How do we lower healthcare costs without weakening the innovation ecosystem that develops new medicines? Charles Crain argues that affordability and innovation are not competing goals, and that policymakers should focus on the structural drivers of healthcare spending rather than policies that could reduce future medical breakthroughs. Check out the NAM report: "Prescription for a Healthy Workforce: Manufacturers' Roadmap to Lower Healthcare Costs" https://nam.org/issues/health-care/  Join the Conversation ⬇️ Are policymakers focusing on the right drivers of healthcare costs? Should PBM reform be a higher priority than drug price controls? What matters most for U.S. competitiveness: tax policy, regulatory certainty, or innovation incentives? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod  Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology. Timestamps 00:00 Intro & Disclaimer 00:37 Meet Charles Crain & NAM 01:03 Why Manufacturers Care About Healthcare Costs 03:24 Why Healthcare Costs Keep Rising 05:57 What NAM Would Do to Lower Costs 08:03 Why Manufacturers Oppose Drug Price Controls 09:20 The Innovation Tradeoff Explained 10:54 Understanding the 340B Program 13:16 PBMs & Healthcare Middlemen 15:09 How Powerful Are PBMs? 17:13 Why FDA Stability Matters 18:16 Regulatory Costs & Uncertainty 19:30 Why Biotech Needs Predictable Rules 20:43 Building Bipartisan Policy Solutions 23:18 Competing With China Through Innovation 25:12 Final Thoughts DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #healthcarepolicy #pbm #biotech #drugpricing #fda #manufacturing #makingmedicine

  8. May 28

    Rep. Scott Peters on the Pill Penalty, PBMs, China & America’s Biotech Future

    China and biotech competition. Drug pricing reform. The FDA. PBMs. America’s innovation economy. This week on the Making Medicine Podcast, John Stanford sits down with Rep. Scott Peters to discuss the future of American biotech innovation, the importance of ending the “pill penalty,” and why China’s rapid rise in biotechnology is becoming a major strategic concern for the United States. Representing one of the country’s leading biotech hubs in San Diego, Congressman Peters explains why policies tied to the Inflation Reduction Act and investment incentives directly impact whether innovative medicines get funded, developed, and brought to patients. The conversation also explores the future of PBM reform, rare disease investment, FDA modernization, the workforce and scientific talent, supply chain security, and what policymakers must do to keep America competitive in biotech and life sciences innovation. This episode covers: 🔹 Why San Diego became a biotech powerhouse 🔹 The “pill penalty” and the EPIC Act 🔹 How the IRA changed biotech investment incentives 🔹 Why rare disease investment rebounded after the ORPHAN Cures Act 🔹 China’s growing role in global biotech innovation 🔹 FDA modernization and regulatory competitiveness 🔹 Immigration, talent, and scientific leadership 🔹 PBM reform and healthcare affordability 🔹 Why diagnostics and genomics may transform healthcare 🔹 The importance of bipartisan problem-solving in healthcare policy At the center of the discussion is one core issue: competitiveness. Congressman Peters argues that America’s advantage in biotech depends on stable investment incentives, strong scientific institutions, private-sector innovation, and policies that continue attracting talent and capital into the United States. Check out more from Incubate Coalition: https://www.incubatecoalition.org/ Join the Conversation ⬇️ Do you think the United States is doing enough to stay competitive with China in biotech innovation? Should Congress further reform the IRA to encourage more biotech investment and drug development? What matters most for the future of American healthcare innovation: FDA modernization, PBM reform, or stronger investment incentives? Let us know your thoughts in the comments below 👇 If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 👍 Like and subscribe for more conversations on FDA policy, biotech investing, healthcare innovation, drug development, gene therapy, AI in medicine, and the future of biotechnology. Timestamps 00:00 Intro & Disclaimer 00:17 Why China Is Catching Up in Biotech 00:31 Meet Congressman Scott Peters 01:28 Why San Diego Became a Biotech Hub 03:24 The Role of NIH & Research Institutions 05:02 Venture Capital & Biotech Growth 07:06 The “Pill Penalty” Explained  08:05 The IRA & Medicare Drug Negotiation 09:25 Why Investment Incentives Matter 11:11 How Small Molecule Investment Was Affected 12:20 Political Risks of Supporting Biotech 15:17 Why Independence Still Matters in Congress 21:26 Rare Disease Investment & Orphan Cures Act 24:00 China’s Rise in Biotech Innovation 25:27 FDA Challenges & Global Competition 27:19 Immigration, Talent & Scientific Leadership 30:25 PBM Reform & Healthcare Costs 33:19 Diagnostics, Genomics & Preventive Medicine 34:19 Why Congress Needs Better Biotech Education 36:35 Closing Thoughts DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #fda #biotech #drugpricing #china #pbm #healthcarepolicy #innovation

See All (86)

Trailer

Ratings & Reviews

5
out of 5
15 Ratings

About

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

Information

  • Creator
    Incubate Coalition
  • Years Active
    2021 - 2026
  • Episodes
    86
  • Rating
    Clean
  • Copyright
    © Copyright Making Medicine Duality
  • Show Website
    Making Medicine

You Might Also Like